Company news

Biogen Inc. news in 2023

Biogen Inc.'s news releases, calls and decks from 2023, newest first.

View company

Biogen Appoints Monish Patolawala to its Board of Directors

November 5, 2023

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

October 24, 2023

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

October 18, 2023

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

September 28, 2023

Biogen Completes Acquisition of Reata Pharmaceuticals

September 25, 2023

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

September 24, 2023

Biogen Appoints Jane Grogan as Head of Research

September 5, 2023

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

August 3, 2023

Biogen to Acquire Reata Pharmaceuticals

July 27, 2023

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

July 5, 2023

Biogen Announces Changes to Its Board of Directors

June 11, 2023

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

April 24, 2023

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

April 11, 2023

Biogen Appoints Adam Keeney as Head of Corporate Development

April 3, 2023

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

March 21, 2023

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

March 15, 2023

Biogen Appoints Chuck Triano as Head of Investor Relations

March 13, 2023

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

March 7, 2023

Biologics License Application for lecanemab designated for Priority Review by china National medical products Administration

February 26, 2023

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

February 5, 2023

Marketing authorization application for lecanemab as treatment for early Alzheimer's disease accepted by European Medicines Agency

January 25, 2023

FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

January 5, 2023

Biogen Names Priya Singhal as Executive Vice President, Head of Development

January 4, 2023

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

January 3, 2023

Calls in 2023

Decks in 2023